Back to discover
Disease
Bronchiectasis
Late-stage therapeutic developmentEmerging research
3
Publications
20
Clinical trials
12
Associated genes
1
Related proteins
2024
Latest publication
Current focus
Therapeutic developmentGenetics & risk factorsDisease mechanisms & pathology
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Marketing authorisation: Brinsupri (EMA)
Regulatory2025-11-18EMA
Research2024-07-17Respiratory research
Pathophysiology and genomics of bronchiectasis.
Research2024-07-03European respiratory review : an official journal of the European Respiratory Society
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q2 2027.
- 2 industry developments reported.
Upcoming Milestones
- Q2 2027A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)
- Q1 2028A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis
- Q1 2029Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis
- Q4 2030Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20272026-10-14
Upcoming trial readoutHigh impact
Results expected Q4 20302026-08-21
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-10-14A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)Results expected Q2 2027
- 2026-08-21Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome DiversityResults expected Q4 2030
- 2026-06-01Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis BronchiectasisResults expected Q1 2029
- 2025-11-10A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis BronchiectasisResults expected Q1 2028
Recently completed
- 2025-12-23Evaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)Completed
- 2025-11-15Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled TrialCompleted
Industry & MarketViewHide
- 2026-11-02More GERD found in bronchiectasis plus Sjögren's syndromeIndustry · Healio Pulmonology
- 2026-10-21More discolored sputum linked to higher bronchiectasis activityIndustry · Healio Pulmonology
Regulatory UpdatesViewHide
- 2025-11-18Original application approval — Brensocatib MonohydrateBrinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
Activity timeline10
- 2026-11-02IndustryMore GERD found in bronchiectasis plus Sjögren's syndromeIndustry · Healio Pulmonology
- 2026-10-21IndustryMore discolored sputum linked to higher bronchiectasis activityIndustry · Healio Pulmonology
- 2026-10-14ClinicalA Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)Results expected Q2 2027
- 2026-08-21ClinicalItraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome DiversityResults expected Q4 2030
- 2026-06-01ClinicalPhase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis BronchiectasisResults expected Q1 2029
- 2025-12-23ClinicalEvaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)Completed
- 2025-12-16ClinicalA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN StudyResults posted
- 2025-11-18RegulatoryOriginal application approval — Brensocatib MonohydrateBrinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
- 2025-11-15ClinicalEfficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled TrialCompleted
- 2025-11-10ClinicalA Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis BronchiectasisResults expected Q1 2028
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Brensocatib Monohydrateapproved
Original application approval — Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in… (2025)
Clinical trials
The current development programme across all trial phases.
Clinical programme
20
6
17
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
Product approvals and authorisations
2025emaOriginal application approval — Brensocatib Monohydrate· Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
Most influential
Major themes8
- Bronchiectasis3
- Arthritis, Rheumatoid1
- Genetic Predisposition to Disease1
- Genomics1
- Hypertension, Pulmonary1
- Lung1
- Lung Diseases, Interstitial1
- Pulmonary Fibrosis1
Leading journals2
- European respiratory review : an official journal of the European Respiratory Society2
- Respiratory research1
Leading researchers8
- Chalmers JD1
- Cheng LL1
- Duan JL1
- Faner R1
- Gao LF1
- Guan WJ1
- Huang PR1
- Jiang Y1
Affiliations (unnormalised)6
- Center for Interstitial Lung Diseases1
- Division of Molecular and Clinical Medicine1
- Guangzhou National Laboratory1
- Hospital Clínic1
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)1
- State Key Laboratory of Respiratory Disease1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Persistent abnormal dilatation of the bronchi.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.